Key facts
- This page summarizes Barbara Lopez Kunz's Form 4 filing for Aptevo Therapeutics Inc. (APVO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jul 2025, 16:42.
Barbara Lopez Kunz - 17 Jul 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)
- Reporting relationship
- Director
- Issuer ticker
- APVO
- Reported as of
- 17 Jul 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2025, 16:42:49 UTC
- Prior SEC filing
- 19 Jul 2024
- Next SEC filing
- 08 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ SoYoung Kwon, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barbara Lopez Kunz filed Form 4 for Aptevo Therapeutics Inc. (APVO) on 21 Jul 2025.
Change
- Previous filing in this sequence was filed on 19 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001679970
Primary reporting owner
Kunz Barbara Lopez
- Relationship
- Director
- Address
- 2401 4TH AVENUE, SUITE 1050, SEATTLE
- Signature
- /s/ SoYoung Kwon, Attorney-In-Fact
- Signature date
- 21 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APVO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1
- Change %
- Price
- Shares after
- 1
- Date
- 17 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APVO
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -1
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 17 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
Footnote F2
On July 17, 2024, the reporting person was granted 925 (1 post-splits) RSUs, vesting in full one year from the date of grant.